Straits Times Index
3,348.87 +12.28 (+0.37%) S&P 500
5,286.51 +9.00 (+0.17%) Dow
38,579.87 -106.45 (-0.28%) Nasdaq
16,832.35 +97.33 (+0.58%) Bitcoin USD
69,809.41 +1,698.02 (+2.49%) CMC Crypto 200
1,504.63 +36.69 (+2.50%)
BHVN Jul 2024 25.000 call
| Previous close | 8.10 |
| Open | 6.00 |
| Bid | 10.30 |
| Ask | 12.80 |
| Strike | 25.00 |
| Expiry date | 2024-07-19 |
| Day's range | 6.00 - 8.10 |
| Contract range | N/A |
| Volume | |
| Open interest | 52 |
PR NewswireBiohaven Showcases Broad Innovative Portfolio and Pipeline Updates Across Multiple Therapeutic Areas including Immunology, Neuroscience, Metabolic Disorders and Oncology at Annual Investor R&D Day
Biohaven Ltd. (NYSE: BHVN) (Biohaven or the Company), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies, provides an overview of its development and regulatory advances across multiple therapeutic areas, and highlights the progress of its innovative degrader pipeline at the Company's 2024 Investor R&D Day today, held concurrently with the Yale Innovation Summit in New Haven, Connecticut. Members of Biohaven's
PR NewswireBiohaven Doses First Patient with its Novel Trop-2 Directed Antibody Drug Conjugate (ADC) BHV-1510 in Advanced or Metastatic Epithelial Tumors
Biohaven Ltd. (NYSE: BHVN) (Biohaven), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat a broad range of rare and common diseases, announced the first patient has been dosed in a first-in-human Phase 1/2 study of BHV-1510, a highly differentiated Trophoblast Cell Surface Antigen-2 (Trop-2) directed Antibody Drug Conjugate (ADC), and the lead ADC program to advance into clinical trials in Biohaven's g
GuruFocus.comDirector Gregory Bailey Acquires 15,000 Shares of Biohaven Ltd (BHVN)
On May 13, 2024, Gregory Bailey, Director of Biohaven Ltd (NYSE:BHVN), purchased 15,000 shares of the company.
